VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Age-related macular degeneration (AMD) affects > 14 million individuals worldwide. Although 90% of patients with AMD have the dry form, neovascular AMD accounts for the vast majority of patients who develop legal blindness. Until recently, few treatment options existed for treatment of neovascular AMD. The advent of anti-VEGF therapy has significantly improved the safe and effective treatment of neovascular AMD. In addition to two anti-VEGF drugs currently in widespread use, ranibizumab and bevacizumab, a number of medications that interrupt angiogenesis are currently under investigation. One promising new drug is aflibercept (VEGF Trap-Eye), a fusion protein that blocks all isoforms of VEGF-A and placental growth factors-1 and -2. OBJECTIVE: To review the current literature and clinical trial data regarding VEGF Trap-Eye for the treatment of neovascular AMD. METHODS: Literature review. RESULTS/CONCLUSION: VEGF Trap-Eye is a novel anti-VEGF therapy, with Phase I and II trial data indicating safety, tolerability and efficacy for the treatment of neovascular AMD. Two Phase III clinical trials (VIEW-1 and VIEW-2) comparing VEGF Trap-Eye to ranibizumab are currently continuing and will provide vital insight into the clinical applicability of this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 4×
“Ranibizumab is the only drug in widespread use currently approved by the FDA for treatment of neovascular AMD and is by far the most extensively studied [26,27,29,30].”
BackgroundMethodInfluentialCauses and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Friedman, D. S. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.7.1019 · Cited by 656
FRANK, R. N., AMIN, R. H., ELIOTT, D., PUKLIN, J. E., & ABRAMS, G. W. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72066-5 · Cited by 366
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
(1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090090052019 · Cited by 303
Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration
D’Amico, D. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.027 · Cited by 260 · cited 2×
“This treatment, in the setting of subfoveal disease, was unsatisfactory for a number of reasons, including the limited benefits in visual stabilization and the high risk of inducing central vision deficits [13].”
Background(1986) · Archives of Ophthalmology · doi:10.1001/archopht.1986.01050170084028 · Cited by 227
Vinores, S. A., Xiao, W., Aslam, S., Shen, J., Oshima, Y., Nambu, H., Liu, H., Carmeliet, P., & Campochiaro, P. A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20525 · Cited by 99 · cited 1×
“VEGF receptors are expressed by a number of important cell types in the eye, including vascular endothelial cells, choroidal fibroblasts, retinal pigment epithelial cells and inflammatory cells attracted by hypoxia [16-19].”
Background
Cited by
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,717
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Corneal Neovascularization: An Anti-VEGF Therapy Review
Chang, J.-H., Garg, N. K., Lunde, E., Han, K.-Y., Jain, S., & Azar, D. T. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.007 · Cited by 381
Rymo, S. F., Gerhardt, H., Wolfhagen Sand, F., Lang, R., Uv, A., & Betsholtz, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015846 · Cited by 235
Nork, T. M. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.210 · Cited by 48
Metadata
- Authors
- Dixon, J. A., Oliver, S. C., Olson, J. L., & Mandava, N.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2009-08-20
- Volume
- 18
- Issue
- 10
- Pages
- 1573-1580
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2090248679
- Cited by
- 135
- References
- 13
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.